Oncogenic KRAS frequently engenders an immunosuppressive milieu through recruitment of suppressive immune subsets such as myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and regulatory T cells. The gene discussed is KRAS; the disease is neoplasm.